Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease.

Rudolf Pihusch1, Andreas Rank, Peter Göhring

  • 1Medizinische Klinik III, Klinikum der Ludwig-Maximilians-Universität - Grosshadern, 81377 München, Germany. rudolf.pihusch@med3.med.uni-muenchen.de

Journal of Hepatology
|October 26, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Leukemic Blood Samples with Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Is Associated with Reduced Frequencies of Tolerogenic Dendritic Cells and Increased Cytotoxicity Against Autologous Blasts.

Biomedicines·2026
Same author

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation.

Alimentary pharmacology & therapeutics·2026
Same author

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Blood·2026
Same author

Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

A Free N-Heterocyclic Carbene and Its Metal Complex.

Angewandte Chemie (International ed. in English)·2026
Same author

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

The Lancet. Haematology·2026

Patients with cholestatic liver diseases, such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), exhibit a hypercoagulable state and altered platelet function compared to non-cholestatic liver diseases. This suggests distinct hemostatic profiles in different chronic liver conditions.

Area of Science:

  • Hepatology
  • Hematology
  • Coagulation Science

Background:

  • Cholestatic liver diseases (primary biliary cirrhosis/primary sclerosing cholangitis) are associated with better outcomes in variceal bleeding and lower blood loss during transplantation.
  • This suggests a potential hypercoagulable state in cholestatic conditions compared to other chronic liver diseases.

Purpose of the Study:

  • To assess and compare plasmatic coagulation and platelet function in patients with cholestatic (PBC/PSC) versus non-cholestatic (hepatitis C/alcoholic cirrhosis) chronic liver diseases.

Main Methods:

  • Evaluated 37 patients with cholestatic liver disease (PBC/PSC), 53 with non-cholestatic liver disease (HCV/alcoholic cirrhosis), and 62 healthy controls.
  • Utilized thrombelastography, PFA-100 closure time, and flow cytometry to analyze coagulation and platelet receptor expression (CD42b, LIBS-1).

Related Experiment Videos

Main Results:

  • Non-cirrhotic PBC/PSC patients showed a hypercoagulable state (higher ma-value, increased fibrinogen) compared to HCV patients.
  • Platelet function was altered in advanced cirrhosis, with prolonged PFA-100 closure time in HCV/C2 patients but not in cirrhotic PBC/PSC patients.
  • PBC/PSC patients exhibited higher surface expression of platelet receptors CD42b and LIBS-1.

Conclusions:

  • Platelet function and coagulation profiles differ significantly between cholestatic and non-cholestatic liver diseases.
  • Patients with primary biliary cirrhosis and primary sclerosing cholangitis demonstrate stable or hyperactive platelet function, contributing to a hypercoagulable state.